ASK PHARM(SZ:002755) 智通财经网·2025-09-02 09:39Core Viewpoint - The company announced that its wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., has completed the first patient dosing in a Phase III registration clinical study for the innovative drug ASKC202 in combination with Lapatinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET amplification/overexpression after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) [1] Group 1 - The innovative drug ASKC202 is being developed for a specific patient population that has not responded to existing EGFR-TKIs [1] - The clinical study is a Phase III registration trial, indicating a significant step towards potential market approval [1] - The focus on MET amplification/overexpression highlights a targeted approach in cancer treatment, which may address unmet medical needs in NSCLC [1]